Progen Subsidiary Secures New Manufacturing Contracts with Prima...

Progen Subsidiary Secures New Manufacturing Contracts with Prima BioMed Ltd
and Phosphagenics Ltd
Brisbane, Australia, 20 July 2011. Progen Pharmaceuticals Ltd (ASX:PGL, OTC: PGLA)
announced today that the company?s biopharmaceuticals manufacturing subsidiary
PharmaSynth Pty Ltd, had secured new contracts with Australian biotech companies, Prima
BioMed Limited and Phosphagenics Limited.
PharmaSynth has been contracted by Prima BioMed to manufacture mannosylated fusion
protein (M-FP). The M-FP will be used as a key starting material in the production of CVac?.
Prima BioMed has a forthcoming pivotal clinical trial (CANVAS) to use CVac?, a ?cellular
therapy? or ?cancer vaccine?, as a maintenance treatment for patients with Epithelial Ovarian
Cancer (EOC) in complete remission. PharmaSynth have previously manufactured M-FP for
Prima BioMed.
PharmaSynth has also been contracted to manufacture TPM? for Phosphagenics. The TPM?
technology which comprises vitamin E phosphates has been shown to enhance dermal,
transdermal and oral absorption of compounds and Phosphagenics is using the technology to
develop therapeutics, nutraceuticals and personal care products. Phosphagenics is a new
client for PharmaSynth.
Progen CEO, Sue MacLeman, said that whilst these individual contracts are not material to
Progen?s overall result, PharmaSynth?s new contract with Prima BioMed and the addition of
Phosphagenics to its growing list of strategic relationships with innovative Australian
biotechnology clients is an important achievement for the growth of PharmaSynth.
PharmaSynth CEO, Les Tillack, said ?These projects fit well with our core areas of expertise
in recombinant protein manufacture and chemical synthesis.?